---
authors:
- Slawson, David C
category: Research Article
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/39172685/
file_path: 2024/08/greater-risk-of-serious-bleeding-with-diltiazem-vs-metoprolo.md
issue: '2'
keywords:
- Atrial Fibrillation
- Humans
- Pyrazoles
- Hemorrhage
- Rivaroxaban
- Metoprolol
- Pyridones
- Diltiazem
- Female
- Male
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Atrial Fibrillation
- Rivaroxaban
- Pyridones
- Pyrazoles
- Hemorrhage
- Diltiazem
- Metoprolol
- Female
- Male
- Factor Xa Inhibitors
- Aged
- Middle Aged
original_format: PubMed
pages: '203'
patient_population: Adults
peer_reviewed: true
pmid: '39172685'
processed_date: '2025-07-30'
publication_date: '2024-08-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-10'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Greater Risk of Serious Bleeding With Diltiazem vs. Metoprolol in Adults With
  Atrial Fibrillation Using Apixaban or Rivaroxaban.
topics:
- Family Medicine
volume: '110'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '39172685'
  title: Greater Risk of Serious Bleeding With Diltiazem vs. Metoprolol in Adults
    With Atrial Fibrillation Using Apixaban or Rivaroxaban.
  authors:
  - last_name: Slawson
    fore_name: David C
    initials: DC
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '110'
    issue: '2'
  publication_info:
    year: '2024'
    month: 08
    full_date: '2024-08-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Atrial Fibrillation
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
    - qualifier: complications
      major_topic: false
  - descriptor: Rivaroxaban
    major_topic: true
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Pyridones
    major_topic: true
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Pyrazoles
    major_topic: true
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Hemorrhage
    major_topic: true
    qualifiers:
    - qualifier: chemically induced
      major_topic: false
    - qualifier: prevention & control
      major_topic: false
  - descriptor: Diltiazem
    major_topic: true
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Metoprolol
    major_topic: true
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Female
    major_topic: false
  - descriptor: Male
    major_topic: false
  - descriptor: Factor Xa Inhibitors
    major_topic: false
    qualifiers:
    - qualifier: adverse effects
      major_topic: false
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Aged
    major_topic: false
  - descriptor: Middle Aged
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '39172685'
  title: Greater Risk of Serious Bleeding With Diltiazem vs. Metoprolol in Adults
    With Atrial Fibrillation Using Apixaban or Rivaroxaban.
  authors:
  - name: Slawson DC
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2024 Aug
- pmid: '38619832'
  title: Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With
    Apixaban or Rivaroxaban.
  authors:
  - name: Ray WA
    authtype: Author
    clusterid: ''
  - name: Chung CP
    authtype: Author
    clusterid: ''
  - name: Stein CM
    authtype: Author
    clusterid: ''
  - name: Smalley W
    authtype: Author
    clusterid: ''
  - name: Zimmerman E
    authtype: Author
    clusterid: ''
  - name: Dupont WD
    authtype: Author
    clusterid: ''
  - name: Hung AM
    authtype: Author
    clusterid: ''
  - name: Daugherty JR
    authtype: Author
    clusterid: ''
  - name: Dickson A
    authtype: Author
    clusterid: ''
  - name: Murray KT
    authtype: Author
    clusterid: ''
  source: JAMA
  pubdate: 2024 May 14
- pmid: '34932078'
  title: Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic
    Events in Patients With Atrial Fibrillation.
  authors:
  - name: Ray WA
    authtype: Author
    clusterid: ''
  - name: Chung CP
    authtype: Author
    clusterid: ''
  - name: Stein CM
    authtype: Author
    clusterid: ''
  - name: Smalley W
    authtype: Author
    clusterid: ''
  - name: Zimmerman E
    authtype: Author
    clusterid: ''
  - name: Dupont WD
    authtype: Author
    clusterid: ''
  - name: Hung AM
    authtype: Author
    clusterid: ''
  - name: Daugherty JR
    authtype: Author
    clusterid: ''
  - name: Dickson A
    authtype: Author
    clusterid: ''
  - name: Murray KT
    authtype: Author
    clusterid: ''
  source: JAMA
  pubdate: 2021 Dec 21
- pmid: '29934230'
  title: Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban
    in patients with non-valvular atrial fibrillation.
  authors:
  - name: Andersson NW
    authtype: Author
    clusterid: ''
  - name: Svanstr√∂m H
    authtype: Author
    clusterid: ''
  - name: Lund M
    authtype: Author
    clusterid: ''
  - name: Pasternak B
    authtype: Author
    clusterid: ''
  - name: Melbye M
    authtype: Author
    clusterid: ''
  source: Int J Cardiol
  pubdate: 2018 Oct 1
- pmid: '38342714'
  title: Safety of apixaban and rivaroxaban in patients with atrial fibrillation on
    hemodialysis.
  authors:
  - name: Ito H
    authtype: Author
    clusterid: ''
  source: Eur J Intern Med
  pubdate: 2024 Jun
---

# Greater Risk of Serious Bleeding With Diltiazem vs. Metoprolol in Adults With Atrial Fibrillation Using Apixaban or Rivaroxaban.

**Authors:** Slawson, David C

**Published in:** American family physician | Vol. 110, No. 2 | 2024-08-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/39172685/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Atrial Fibrillation, Rivaroxaban, Pyridones, Pyrazoles, Hemorrhage, Diltiazem, Metoprolol, Female, Male, Factor Xa Inhibitors, Aged, Middle Aged

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/39172685/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
